Ameriprise
ELVN icon

Ameriprise’s Enliven Therapeutics ELVN Stock Holding History

Ameriprise’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.7M Buy
251,192
+90,615
+56% +$3.85M ﹤0.01% 1877
2026
Q1 		$6.29M Buy
160,577
+141,628
+747% +$3.92M ﹤0.01% 2285
2025
Q4 		$292K Sell
18,949
-104,387
-85% -$2.08M ﹤0.01% 3811
2025
Q3 		$2.52M Buy
123,336
+64,092
+108% +$1.29M ﹤0.01% 2890
2025
Q2 		$1.19M Buy
59,244
+35,582
+150% +$674K ﹤0.01% 3193
2025
Q1 		$466K Sell
23,662
-11,397
-33% -$245K ﹤0.01% 3516
2024
Q4 		$789K Buy
+35,059
New +$909K ﹤0.01% 3343

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Ameriprise's ELVN Position: Q2 2026 in Review

Ameriprise increased its Enliven Therapeutics (ELVN) stake by 56% in Q2 2026, buying an estimated $3.85M and bringing the position to 251,192 shares worth $12.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1877.

Ameriprise first reported a position in ELVN in Q4 2024 and has held it in 7 quarters since. 212 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Ameriprise held 251,192 shares of Enliven Therapeutics worth $12.7M as of Q2 2026.
  • Ameriprise bought 90,615 Enliven Therapeutics shares in Q2 2026, an estimated $3.85M.
  • Enliven Therapeutics made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #1877 holding.
  • Ameriprise first reported a position in Enliven Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 212 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.